MAP2K7 and malignant colon neoplasm: Notably, functional crosstalk occurs between the PI3K/Akt and Ras/Raf/MEK/ERK pathways in colon cancer cells, as the downregulation of one pathway corresponds with the upregulation of the other; however, treatment with both patritumab (a PI3K inhibitor) and trametinib (an MEK inhibitor) reduces the viability of said cells [117].